Business Context and Reporting Period
This Form 8-K Current Report, dated March 20, 2008, is filed by PharmAthene, Inc. (not Altimmune, Inc., as indicated in the metadata). The filing discloses the entry into a Material Definitive Agreement for the acquisition of Avecia Biologics Limited's vaccines business and a concurrent modification to the Company's existing credit facility.
Key Financial Metrics and Transaction Terms
The filing details a significant acquisition and financing arrangement rather than standard periodic financial results. Key financial terms include:
- Acquisition Consideration:
- Initial Payment: $10 million (exclusive of VAT) at consummation, subject to a working capital adjustment based on a $100,000 threshold.
- Deferred Payment: An additional $10 million (exclusive of VAT) payable upon the earlier of a $15 million financing or the first anniversary of the acquisition, secured by a letter of credit.
- Milestone Payments:
- $10 million upon securing a multi-year US Department of Defense contract for the plague vaccine (rYP) exceeding $150 million.
- $5 million upon securing a BARDA contract for the anthrax vaccine (rPA).
- $5 million upon securing a contract for the Strategic National Stockpile.
- 2.5% of net sales of rPA vaccine to the US government (after the first 25 million doses) for ten years.
- 1% of net sales of third-generation anthrax vaccine to the US government for ten years.
- Existing Debt: The Company has a $10 million secured credit facility with Silicon Valley Bank and Oxford Finance Corporation bearing 11.5% annual interest.
- Liquidity Covenants: The modified loan agreement requires the Company to maintain unrestricted cash or cash equivalents equal to at least 1.25 times all obligations to the Lenders in a segregated account.
Material Changes and Agreements
The primary material change is the execution of the Sale and Purchase Agreement with Avecia Biologics Limited to acquire assets related to:
- A second-generation recombinant protective antigen (rPA) anthrax vaccine.
- A recombinant dual antigen plague vaccine.
- A third-generation rPA anthrax vaccine program.
Additionally, the Company entered into a Consent and First Loan Modification Agreement with its lenders to permit the acquisition. This agreement imposes new conditions, including requiring the UK subsidiary to become a co-borrower or secured guarantor within 20 days of consummation and granting lenders a first perfected security interest in accounts held at M&T Bank.
Outlook, Risks, and Contingencies
Conditions to Consummation: The acquisition is contingent upon receiving consents and approvals for the transfer of contracts with the UK Ministry of Defence, the US National Institutes of Health (NIH), and the NIH Challenge Grant.
Risks and Uncertainties: The filing includes forward-looking statements regarding the expected benefits of the transaction. The Company explicitly states it can give no assurance that the transaction will be consummated or that conditions will be met. Risks include the failure to secure necessary government contract transfers and the potential for actual results to vary materially from projections.
Management Commentary: The Company intends to secure the deferred $10 million payment via a letter of credit issued by Silicon Valley Bank. Ancillary agreements for transitional services and long-term manufacturing supply by Avecia are also planned.
Investor Verification Checklist
- Verify the status of regulatory consents required for the transfer of UK Ministry of Defence and US NIH contracts.
- Confirm the issuance of the $10 million letter of credit by Silicon Valley Bank to secure the deferred payment.
- Monitor the Company's cash position to ensure compliance with the new 1.25x liquidity covenant.
- Track progress on securing the specific government contracts (DoD, BARDA, Strategic National Stockpile) required to trigger milestone payments.
- Review the full text of the Sale and Purchase Agreement (Exhibit 2.1) and Loan Modification Agreement (Exhibit 10.1) for detailed covenants and definitions.